J.J. Lafitte

1.2k total citations
39 papers, 930 citations indexed

About

J.J. Lafitte is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, J.J. Lafitte has authored 39 papers receiving a total of 930 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in J.J. Lafitte's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (5 papers). J.J. Lafitte is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (5 papers). J.J. Lafitte collaborates with scholars based in France, Belgium and Spain. J.J. Lafitte's co-authors include Marianne Paesmans, Elizabeth Steels, Jean‐Paul Sculier, Thierry Berghmans, Frédéric Vallot, Anne‐Pascale Meert, Fabrice Branle, F. Lemaı̂tre, Céline Mascaux and T. Berghmans and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Respiratory Journal.

In The Last Decade

J.J. Lafitte

36 papers receiving 895 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.J. Lafitte France 13 504 481 296 190 126 39 930
M. Paganuzzi Italy 16 331 0.7× 518 1.1× 257 0.9× 99 0.5× 111 0.9× 38 992
M. Veslemes Greece 16 788 1.6× 563 1.2× 350 1.2× 92 0.5× 197 1.6× 39 1.0k
R.-P. Perng Taiwan 18 535 1.1× 440 0.9× 318 1.1× 82 0.4× 70 0.6× 47 950
William H. Isacoff United States 16 499 1.0× 223 0.5× 152 0.5× 146 0.8× 138 1.1× 25 804
Reury-Perng Perng Taiwan 20 598 1.2× 748 1.6× 164 0.6× 86 0.5× 143 1.1× 51 1.1k
Ewa Kalinka‐Warzocha Poland 18 504 1.0× 363 0.8× 160 0.5× 169 0.9× 60 0.5× 91 944
E. Papadakis Greece 18 1.1k 2.2× 756 1.6× 544 1.8× 115 0.6× 299 2.4× 40 1.4k
N. J. Vogelzang United States 16 302 0.6× 290 0.6× 286 1.0× 89 0.5× 41 0.3× 38 759
William H. Liggett United States 10 588 1.2× 411 0.9× 522 1.8× 139 0.7× 69 0.5× 16 1.2k
Christian Monnerat Switzerland 14 361 0.7× 190 0.4× 187 0.6× 66 0.3× 106 0.8× 34 645

Countries citing papers authored by J.J. Lafitte

Since Specialization
Citations

This map shows the geographic impact of J.J. Lafitte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.J. Lafitte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.J. Lafitte more than expected).

Fields of papers citing papers by J.J. Lafitte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.J. Lafitte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.J. Lafitte. The network helps show where J.J. Lafitte may publish in the future.

Co-authorship network of co-authors of J.J. Lafitte

This figure shows the co-authorship network connecting the top 25 collaborators of J.J. Lafitte. A scholar is included among the top collaborators of J.J. Lafitte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.J. Lafitte. J.J. Lafitte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Balduyck, Malika, Marie‐Françoise Odou, Farid Zerimech, et al.. (2014). Diagnosis of alpha-1 antitrypsin deficiency: Modalities, indications and diagnosis strategy. Revue des Maladies Respiratoires. 31(8). 729–745. 10 indexed citations
2.
Bouchindhomme, B., Nunzia Tacelli, X. Dhalluin, et al.. (2013). La maladie de Castleman : observations inhabituelles et revue de la littérature. Revue de Pneumologie Clinique. 69(1). 55–59. 1 indexed citations
3.
4.
Dakpé, Stéphanie, et al.. (2012). Énophtalmie de la cavité anophtalme : incidence de la morphologie orbitaire et implications thérapeutiques. Étude clinique de 86 cas. Annales de Chirurgie Plastique Esthétique. 57(6). 549–557. 3 indexed citations
5.
Sculier, Jean‐Paul, J.J. Lafitte, Marianne Paesmans, et al.. (2007). Chemotherapy improves low performance status lung cancer patients. European Respiratory Journal. 30(6). 1186–1192. 20 indexed citations
6.
Berchier, M.C., Thierry Berghmans, Benoît Colinet, et al.. (2007). European Lung Cancer Working Party Clinical Practice Guidelines. Small Cell Lung Cnacer: IV. Limited disease. 2(2). 74–82. 1 indexed citations
7.
Zerimech, Farid, et al.. (2007). Evaluation of a new Sebia isoelectrofocusing kit for α1-antitrypsin phenotyping with the Hydrasys® System. Clinical Chemistry and Laboratory Medicine (CCLM). 46(2). 260–3. 36 indexed citations
8.
Makris, Demosthènes, Arnaud Scherpereel, M.C. Copin, et al.. (2007). Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer. 7(1). 150–150. 48 indexed citations
9.
Berghmans, T., M. Paesmans, Céline Mascaux, et al.. (2006). Thyroid transcription factor 1—a new prognostic factor in lung cancer: a meta-analysis. Annals of Oncology. 17(11). 1673–1676. 111 indexed citations
10.
Berghmans, T., J.J. Lafitte, Marianne Paesmans, et al.. (2005). A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer. 50(1). 75–82. 22 indexed citations
11.
Durand-Joly, Isabelle, Magali Chabé, Jean Hugues Dalle, et al.. (2003). Long‐Term Colonization with Pneumocystis jirovecii in Hospital Staffs: A Challenge to Prevent Nosocomial Pneumocystosis. Journal of Eukaryotic Microbiology. 50(s1). 614–615. 31 indexed citations
12.
Sculier, Jean‐Paul, J.J. Lafitte, J. Lecomte, et al.. (2002). A phase II randomised trial comparing the cisplatin–etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Annals of Oncology. 13(9). 1454–1459. 16 indexed citations
13.
Berghmans, T., M Paesmans, J.J. Lafitte, et al.. (2002). Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. Supportive Care in Cancer. 10(3). 181–188. 58 indexed citations
14.
Sculier, Jean‐Paul, T. Berghmans, Marianne Paesmans, et al.. (2001). [The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers].. PubMed. 22(6). 477–87. 4 indexed citations
15.
Lafitte, J.J.. (2001). Michel Grosclaude / Jean-François Le Nail avec intégration des travaux de Jacques Boisgontier (1998), Dictionnaire toponymique des communes des Hautes-Pyrénées, 2000. 37(1). 343–349. 1 indexed citations
16.
Steels, Elizabeth, Marianne Paesmans, Thierry Berghmans, et al.. (2001). Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. European Respiratory Journal. 18(4). 705–719. 337 indexed citations
17.
Sculier, J.P., Vincent Ninane, Anna Efremidis, et al.. (1999). The First World Conference on Clinical Cooperative Research for Lung Cancer, Brussels 4–6 March 1999☆. Lung Cancer. 26(2). 113–116.
18.
Jp, Sculier, Marianne Paesmans, J Thiriaux, et al.. (1998). Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.. Journal of Clinical Oncology. 16(4). 1388–1396. 24 indexed citations
19.
20.
Vindimian, M, et al.. (1984). Valeur d'un nouveau marqueur tumoral, le CA 19-9, dans les cancers primitifs des bronches.. La Presse Médicale. 13(29). 1787–1787. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Paganuzzi Breakdown of academic impact, for papers by M. Veslemes Breakdown of academic impact, for papers by R.-P. Perng Breakdown of academic impact, for papers by William H. Isacoff Breakdown of academic impact, for papers by Reury-Perng Perng Breakdown of academic impact, for papers by Ewa Kalinka‐Warzocha Breakdown of academic impact, for papers by E. Papadakis Breakdown of academic impact, for papers by N. J. Vogelzang Breakdown of academic impact, for papers by William H. Liggett Breakdown of academic impact, for papers by Christian Monnerat
Rankless by CCL
2026